HighTide Phase 2 in primary sclerosing cholangitis in the U.S., Canada, topline results expected in 2H2020
May 8, 2020HighTide is expecting to finalize the data analysis and is preparing submissions for presentation and peer-reviewed publication.
Jeffrey Dao, Operating Officer & Business Development Officer told Pharmaceutical Daily that in parallel, the company expects to complete a Phase 2 in primary sclerosing cholangitis in the U.S. and Canada, with topline results in 2H2020.
“Given the safety profile and beneficial effects of HTD1801, we see great potential for these indications, and anticipate exploration of other indications as well,” he told Pharmaceutical Daily.
On Thursday, HighTide Therapeutics said that its HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes, as HTD1801 demonstrated broad beneficial effects in measures of glycemic control, liver injury and cardiovascular risk factors.
